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Due to the significant interest in Monte Carlo dose calculations for external beam megavoltage
radiation therapy from both the research and commercial communities, a workshop was held in
October 2001 to assess the status of this computational method with regard to use for clinical
treatment planning. The Radiation Research Program of the National Cancer Institute, in conjunc-
tion with the Nuclear Data and Analysis Group at the Oak Ridge National Laboratory, gathered a
group of experts in clinical radiation therapy treatment planning and Monte Carlo dose calculations,
and examined issues involved in clinical implementation of Monte Carlo dose calculation methods
in clinical radiotherapy. The workshop examined the current status of Monte Carlo algorithms, the
rationale for using Monte Carlo, algorithmic concerns, clinical issues, and verification methodolo-
gies. Based on these discussions, the workshop developed recommendations for future NCI-funded
research and development efforts. This paper briefly summarizes the issues presented at the work-
shop and the recommendations developed by the group. © 2003 American Association of Physi-
cists in Medicine. @DOI: 10.1118/1.1626990#
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In recent years, there has been widespread interest in the
implementation of Monte Carlo ~MC! dose calculation algo-
rithms for megavoltage external beam radiation therapy for
routine clinical treatment planning. To evaluate the current
status of this use of MC, the National Cancer Institute, in
association with the Oak Ridge National Laboratory, orga-
nized a workshop entitled ‘‘Issues Limiting the Clinical Use
of Monte Carlo Dose Calculation Algorithms’’ in Gatlinburg,
TN in October 2001. Attendees included experts in clinical
radiation oncology, clinical treatment planning, and MC cal-
culation algorithm development and study.
The primary goal of the workshop was the combination of
the ideas of all three types of experts to identify issues re-
quiring additional work and support in order to make pos-
sible the routine clinical use of MC dose calculations for
external beam radiation therapy treatment planning. Specific
Monte Carlo codes, their advantages or disadvantages, or
commercial MC applications, were not in general discussed.
Rather, the goal was to concentrate only on the scientific and
clinical issues, particularly those which would benefit from
discussion between the clinical and MC experts present at
the workshop.
This report gives a brief summary of the workshop dis-
cussions, and lists the recommendations for future National
Cancer Institute research and development funding which
were developed by the workshop. This paper is not a review,3206 Med. Phys. 30 12, December 2003 0094-2405Õ2003Õ30a description of Monte Carlo research efforts, or a complete
description of all relevant Monte Carlo dose calculations is-
sues or results, but rather a summary of the issues discussed
at the workshop.
II. BRIEF OVERVIEW: MONTE CARLO METHODS
FOR RADIOTHERAPY DOSE CALCULATIONS
Monte Carlo dose calculation algorithms for radiotherapy
use the basic physics of particle interactions to simulate the
deposition of energy ~i.e., dose! in the patient.1–4 The MC
method propagates individual particles ~photons, electrons,
etc.! through the treatment machine, and then through the
patient, tracking each particle history to determine where en-
ergy is deposited along the particle tracks. Individual particle
histories are simulated, based on known particle interaction
cross sections, particle transport, and energy deposition char-
acteristics. Often, a very large number ~millions to billions!
of particles must be simulated in order to obtain a reasonably
precise estimate of the quantities of interest ~e.g., dose!, so
MC methods require significant computational resources. Al-
though often quite time consuming, the MC method is the
calculation algorithm that most closely models the actual
physics of the energy deposition process, so MC algorithms
are expected to be capable of more accuracy than other kinds
of calculation algorithms.
Any megavoltage external beam Monte Carlo dose calcu-
lation must handle two different parts of the dose calculation320612Õ3206Õ11Õ$20.00 © 2003 Am. Assoc. Phys. Med.
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therapy machine collimation system, and ~2! the calculation
of dose within the patient, based on the beam which exits
from the accelerator head. The latest versions of general-
purpose Monte Carlo codes currently in distribution ~EGS4,5
EGSNRC,6 ETRAN,7 FLUKA,8 GEANT,9 ITS,10 MCNP,11
PENELOPE12! are generally capable of meeting the basic ac-
curacy requirements of radiotherapy, though many have limi-
tations as well. However, they are all generally too slow,
taking many hours or days to complete a calculation in the
patient ~not including the fixed machine-dependent part of
the problem!. To address this problem, several codes have
been developed more specifically for use in radiotherapy,
including MCDOSE,13 MCPAT,14 DPM,15 PEREGRINE,16,17
VMC11,18 XVMC,19 MMC,20 and Super Monte Carlo.21 These
codes have reduced the calculation times in the patient-
dependent part of the problem, in some cases by an order of
magnitude or more, sometimes through approximations or
compromises including modified electron transport, limited
tracking of low probability events, voxel-based transport
methods, etc. Careful validation and study of such approxi-
mations is of course necessary, and more study of these
newer algorithms is required. How to optimize the MC dose
calculation method to handle both the machine-dependent
and patient-dependent parts of the calculation remains one of
the major questions affecting clinical use of this technology.
The rationale for using MC dose-calculation algorithms
for clinical planning include improved accuracy for ~1! inho-
mogeneities, ~particularly for lung and bony anatomy!, ~2!
tissue interfaces ~lung interfaces, the airway, sinuses!, and
~3! very small fields ~including those used in IMRT treat-
ments! that also exhibit lateral electron disequilibrium ef-
fects. Other expected advantages of Monte Carlo include the
following:
~a! The improved accuracy of MC techniques should apply
to all anatomic geometries, all modalities and all shap-
ing devices.
~b! MC should lead to increased confidence in the accu-
racy of dose distributions.
~c! MC should eliminate the need to develop new and
more complex dose calculation models.
~d! MC should eliminate the laborious trial and error pa-
rametrization which is necessary with most current
model-based calculation algorithms.
~e! MC algorithms may reduce the amount of measured
dose distribution data required for beam and dose cal-
culation characterization during new machine commis-
sioning.
~f! MC will allow direct calculation of monitor units,
hopefully leading to a reduction in the probability of
human mistakes.
~g! MC should allow accurate estimation of quantities dif-
ficult or impossible to measure ~for instance, dose per-
turbations from small inhomogeneities in vivo!.Medical Physics, Vol. 30, No. 12, December 2003III. ISSUES FOR MONTE CARLO ALGORITHMS
Most general purpose MC codes, when applied to the
megavoltage radiotherapy problem, are too slow and cum-
bersome. To gain speed, most MC algorithms designed for
use in planning divide the calculation into three different
parts, including ~1! the fixed beam in the head of the ma-
chine, ~2! propagation through the field-dependent collima-
tion and beam modifiers, and ~3! the transport through the
patient. The first session of the workshop reviewed the status
of some current MC algorithms with respect to the following
basic components of MC algorithms.
A. Photon transport and cross sections
The first part of a Monte Carlo dose calculation simulates
the radiation transport through the head of the treatment ma-
chine ~x-ray target, flattening filter, monitor unit chamber,
primary collimator! and converts the electron beam into a
relatively flat, wide beam of x-ray photons. This is a time
intensive calculation due to the transport of electrons through
the high atomic number materials used in the head, and sig-
nificant absorption of photons by the primary collimator and
flattening filter means that more particles must be simulated
in order to achieve a statistically meaningful result, contrib-
uting to the relative inefficiency of the treatment head simu-
lation. However, the treatment head simulation is typically
only conducted once, for each beam energy, since it is typi-
cally assumed that the linear accelerator remains stable with
respect to beam energy.16,22–24
The field-specific parts of the calculation involve trans-
port through beam modifiers that significantly attenuate parts
of the photon field. Unfortunately, this also implies a large
number of photon interactions and consequently a large
amount of computer time. Approximations for this aspect of
the calculation have been attempted,25 but are not without
difficulties.17
Transport within the patient is also time consuming. The
patient is typically described by a CT grid, that has a fine
resolution relative to the photon mean free path; so each
photon experiences many boundary crossings, each of which
increases the computational effort. Various methods have
been developed to address this problem.17,26–29
The three main photon interaction processes that occur are
photoionization, Compton scattering, and the production of
electron–positron pairs. A detailed review of the state of the
various cross-section data sets was presented. In general it
was felt that the quality of these data were not the limiting
factor in current MC implementations, however, sensitivity
studies are needed to further test that hypothesis. Differences
in bremsstrahlung data resulting in differences in absolute
photon output have been reported in machine modeling stud-
ies. Preliminary studies of the sensitivity of calculations to a
free versus bound Compton scattering model were also dis-
cussed, and more formal benchmark trials that test the un-
derlying data and their effect on accuracy and efficiency
were suggested.
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Electron transport is a crucial component of any external
beam MC calculation method, since photons set electrons
into motion and the electrons then deposit energy in tissue.
The transport of electrons is an important aspect of the cal-
culation that involves very large numbers of smaller interac-
tions due to the long-range Coulomb force. Collision-by-
collision transport of electrons is clearly untenable for
practical applications, so most radiotherapy MC codes utilize
the condensed history method.7,30 In this method, the elec-
tron’s path is divided into sub-steps, and the energy loss and
angular deflection at each step are averaged over many indi-
vidual collisions. Electron transport algorithms are often cat-
egorized as Class I or II models based on how the energy of
the primary electron is related to the energy lost in individual
interactions ~MCNP,11 ETRAN,7 EGS45,6!. Since the electron
transport may be crucial to some radiotherapy calculations,
further investigation and validation of electron transport al-
gorithms is needed.
C. Photoneutron transport and cross sections
Many therapy accelerators use energies high enough to
involve photon–neutron interactions. Fairly comprehensive
photoneutron cross sections are available for major body el-
ements such as C, N, O, and Ca within the photon therapy
energy range of interest. Data on specific particle production
channels are often missing, though there is an excellent sum-
mary of current photonuclear measured data compiled by the
International Atomic Energy Agency.31 The photonuclear
component contributes very little to energy deposition in the
human body, and since one can decrease this component fur-
ther by lowering the energy of the beam, it is reasonable to
question the need for further detailed investigations of this
process with MC. This effect is likely very small in tissue
and most neutrons will escape the patient volume. However,
the activation of metallic implants has yet to be investigated
in detail, and requires more effort.
Neutron generation in machine elements and in therapy
room shielding is a problem recognized in the clinical set-
ting. Photoneutron production is a measurable quantity in the
treatment room, and there are suggestions that it might limit
the time the therapist can spend near the facility. Measure-
ments in clinical settings are now being undertaken by some
researchers, although these quantities are difficult to measure
due to the mixed radiation fields and the large uncertainties
associated with the data.32–34
D. Patient tissue identification issues
A number of techniques have been used to correlate CT
number with a particular elemental tissue compound and cor-
responding mass density, since these are important pieces of
information required by Monte Carlo methods. The photon
mass attenuation coefficient for various tissue compounds, as
defined by ICRU 44,35 shows that all tissue compounds are
basically identical for the radiotherapy energy range of inter-
est ~0.1–10 MeV!, since Compton scattering is the dominantMedical Physics, Vol. 30, No. 12, December 2003photon interaction process, and it is only dependent on the
electron density of the materials. Considering energy depo-
sition, only adipose tissue and cortical bone show large dif-
ferences in total electron stopping power relative to water,
mainly due to the lower atomic number of fat and the higher
atomic number of cortical bone. To improve the consistency
of the various MC algorithms, however, it would be useful to
utilize a consistent method for conversion of CT numbers-to-
tissue identification ~the analysis of Schneider et al. could
serve as a good starting point36!.
E. Variance reduction techniques
One of the unusual aspects of Monte Carlo dose calcula-
tions is that evaluation of the dose distributions has to ac-
commodate the fact that MC uses a stochastic technique, so
there is a variance associated with the dose result at each
point. Since increasing the precision ~and decreasing the
variance! can require significant additional calculation time,
variance reduction is an important topic of current research.
Improved variance reduction techniques may help decrease
calculation time if they can be applied with appropriate care.
In addition, variance reduction is a good example of an issue
that clinical medical physicists and physicians must under-
stand in order for MC calculations to be accepted ~and prop-
erly used! in the clinic. Further education in this area is
clearly warranted, particularly with the goal of describing the
differences between statistical variance reduction, systematic
errors, and de-noising, since these issues are sometimes con-
fused.
F. Machine description andÕor source modeling
Describing the radiation beam which comes from the ac-
celerator; and commissioning the dose calculation results,
which are obtained from the Monte Carlo dose calculation
algorithm ~i.e., assuring that the calculation results agree
with measured data for the particular machine being mod-
eled!, are very important aspects of any dose calculation
model, and this is still true for Monte Carlo dose calculation
algorithms. Accurate simulations of radiation transport in the
treatment machine ~and then the patient! rely on knowing the
characteristics of the radiation beam that comes through the
machine’s head, and in principle includes knowing the posi-
tion, velocity, direction of motion, charge, and energy of
each particle which contributes to the output of the machine.
Since the clinical physicist cannot measure these physical
phenomena directly, this can become a daunting task at the
level of the treatment planning facility.
For Monte Carlo dose calculations in the patient, the most
common way to obtain this description of the beam is to
perform a Monte Carlo simulation of the beam, typically
starting with the electron beam impinging on the photon tar-
get of the machine, and propagating all the particles created
throughout the machine. Much of the work on this aspect of
the process has made use of the BEAM code, developed by
the Omega/Beam project collaboration.22 Since the machine
head simulations require a great deal of calculation, the
simulation is typically performed just once for each machine
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tions in the head above the collimator jaws or any other
moving parts of the collimation system. The MC calculation
for each radiation field then begins from this starting point.
Several different approaches with regard to the head
simulation data are used for patient MC calculations. The
‘‘phase space’’ method records the location, direction, and
energy of each particle in the head simulation at some scor-
ing plane located above all the movable parts of the collima-
tion system. This phase space description is then the input
into the MC calculation used for the field- and patient-
specific dose calculation. The storage requirement for the
phase-space files generated by this method, containing mil-
lions of photons and electrons, are very large ~tens of
gigabytes37!. Before this kind of method can be used for
clinical calculations, the MC simulation of each beam in the
radiotherapy clinic must be performed, a calculation that is
time consuming and dependent on detailed knowledge of the
accelerator head geometry and materials. The correctness of
the phase space description must be confirmed by compre-
hensive commissioning checks ~comparisons of calculation
results and measurements!. Correctly performing these cal-
culations and checks requires a high level of sophistication
and experience with Monte Carlo calculations.
Rather than directly using the phase space data, it is also
possible to create a model of the phase space distribution that
recreates the phase space without saving the actual distribu-
tion of particles. Making use of a source model can save
considerably on disk space.24,37–41 Using such a source
model, the phase space can be reconstructed and fed into the
dose calculation code one particle at a time, eliminating the
need to store phase-space data. This approach has been used
for both photon beams42,43 and electron beams.44 Another
method which has been used is based more directly on mea-
sured input data, analogous to the way many current non-
Monte Carlo algorithms use measurement-determined pa-
rameters.
A number of issues remain to be solved for source mod-
eling and beam commissioning. How sensitive the different
MC approaches are to machine-specific variations ~in accel-
erator tuning, mechanical tolerances, materials, etc.! is not
known ~see Sec. V D!. Differences that result from use of the
phase space description directly versus that of a source
model have not been completely described. Comprehensive
verification of any source model should be performed, and
the verification criteria that will be used should be further
investigated. Currently, source model accuracy is determined
by the agreement between measured dose distributions in
different phantoms and the calculated doses using the recon-
structed beam data, but other end points ~e.g., particle flu-
ence or energy and angular distribution! may be necessary.
Development of effective and efficient beam commissioning
methods and software will facilitate the widespread clinical
application of MC treatment planning.Medical Physics, Vol. 30, No. 12, December 2003IV. MONTE CARLO DOSE CALCULATIONS IN THE
CLINIC
A. How will improved accuracy be used by the clinic?
In the treatment of cancer with radiation, the radiation
oncologist must select a treatment regimen that will have a
high probability of curing or controlling the disease while
not inflicting undue and/or unexpected complications on the
patient. Determining the best way to perform the treatment is
made difficult by many factors including the basic dose-
response relationships for both tumor and normal tissue. In
general, published clinical and experimental results show tu-
mor control or normal tissue effect response as a very steep
function of radiation dose. For example, a small change in
the dose delivered ~65%! can result in a dramatic change in
the local response of the tissue ~620%!.45,46 Moreover, the
prescribed curative doses are comparable to and often exceed
normal tissue tolerance doses. Thus, for optimal treatment,
the radiation dose must be planned and delivered with a high
degree of accuracy. While it is difficult to assess how accu-
rate the overall process should be, the ICRU47 recommends
that dose be delivered with an error less than 5%. Thus, each
step ~machine calibration, patient positioning, dose calcula-
tion, etc.! needs to be performed to an accuracy much better
than 5%. For the dose calculation step, the necessary accu-
racy is believed to be on the order of 2%–3%.48
The gain to each individual patient from the use of more
accurate dose distributions is not measured simply as the
difference in dose calculated by current and improved meth-
ods, as the difference will be relatively small in most cases.
Rather, the gain will be reflected by either increasing prob-
ability of tumor control and/or decreasing rates of complica-
tions, both of which are results that may become more prob-
able if more precise knowledge of the dose distributions is
available. More accurate dose distributions should allow
physicians to make better clinical planning decisions, once
the more accurate doses are correlated with clinical knowl-
edge. Most treatment plans today include margins for safety
that make complications rare, so improved compliance with
physician specified tolerance limits due to MC calculations
may be hard to demonstrate. On the other hand, tumor recur-
rences are common events, and the opportunity provided by
more accurate dose calculations to raise tumor dose without
violating specified constraints in normal tissues can be used
to advantage in clinical practice. Likewise, consistently more
accurate dose calculations will enhance clinical research by
potentially ‘‘sharpening’’ the dose response curves and thus
increasing our knowledge about the radio-response of dis-
eased and normal tissues.
As optimization techniques in radiotherapy delivery im-
prove, one will be able to treat the tumor to the highest dose
possible while keeping the dose to critical tissues at their
tolerance limits. When plans are optimized in this way, tu-
mor dose is found to be very sensitive to the exact specifi-
cation of the dose constraints: variations as small as a few
percent in the specification of a volume fraction that can
exceed a critical dose can cause a much larger change in the
minimum tumor dose which can be delivered,49 and this can
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similar effect on minimum tumor dose can be seen when the
dose homogeneity limit for the target is varied.50 The small
variations in the dose specifications that induce these large
changes in minimum tumor dose fall well within the range of
uncertainty in current estimates of the dose distributions. The
tolerance limits themselves can become better refined by al-
lowing better correlations between dose and adverse events
in large scale clinical trials, a research topic which would
benefit from improved support.
B. Is electron Monte Carlo useful andÕor necessary in
the clinic?
Electron beam treatments typically represent about 10%–
15% of the daily workload in clinical practices, and are used
prominently as boosts for relatively superficial targets. For
this kind of standard use, the electron beam to be used is
chosen clinically, and the dose distributions are generated
primarily for treatment documentation. There has also been
some sophisticated clinical use of electron beams which
might benefit from improved dose calculation accuracy ~as
compared to the standard clinical use described earlier!, but
the limited accuracy of current non-Monte Carlo algorithms,
even three-dimensional pencil beam algorithms, has prob-
ably impeded the integration of sophisticated electron treat-
ment planning into routine clinical practice. Significant dif-
ferences between pencil beam dose distributions and MC
calculations have been demonstrated, particularly in regions
near air cavities and/or bones, with oblique incidence, small
irregular fields, and with extended SSDs.51 As electron beam
Monte Carlo algorithms begin to appear in commercial plan-
ning systems, it will be important to explore the treatment
planning situations in which accurate dose calculations will
be critical—including small fields, electron IMRT implemen-
tations, clinical sites with bone or low density tissues, and
complex delivery techniques like electron arc therapy or the
use of MLCs for electron beams. Further research in Monte
Carlo based electron dose calculations will be important for
these clinical uses.
C. Monte Carlo and IMRT
Monte Carlo calculation algorithms may find significant
importance for Intensity Modulated Radiation Therapy
~IMRT! planning, and a number of issues in this area need to
be considered.52,53
~1! IMRT is typically delivered with either a dynamic or
static sequence of small fields, so techniques need to be de-
veloped for modeling the intricate MLC designs in a ‘‘suffi-
ciently’’ accurate way, while at the same time allowing the
calculations to be performed rapidly. IMRT is one of several
techniques which involve relatively small field irradiation
techniques ~stereotactic radiosurgery is another!, and this is
an area of radiation oncology in which Monte Carlo dose
calculations may make a significant difference,54 since lateral
disequilibrium effects can become large, and the differences
can be further exacerbated by the presence of low density
tissue heterogeneities.Medical Physics, Vol. 30, No. 12, December 2003~2! Depending on the type of inverse planning or optimi-
zation approach that is used, IMRT dose distribution calcu-
lations need to be repeated hundreds, or even thousands of
times during the optimization process. Schemes must be de-
veloped to accomplish this expeditiously without compro-
mising the accuracy afforded by MC techniques.
~3! It is well known that for situations like single beams
passing through slab-like low density inhomogeneities, con-
ventional calculation methods can lead to very large errors
near the beam boundaries or even in the middle of a small
beam, especially for high energies. Superposition/
convolution algorithms improve on this result, but are very
much slower, and do not remove all the errors. MC can give
improved accuracy for these potentially crucial aspects of the
IMRT planning process, especially if increased calculation
time does not overshadow the improved accuracy of the cal-
culations.
~4! IMRT deliveries depend on complex MLC shapes for
which the calculation of head scatter effects is exceedingly
difficult, yet increasingly important. MC should be able to
provide accurate calculation of the head scatter for the very
complex DMLC ~dynamic MLC: movement of the MLC
with the beam on! or SMLC ~segmental MLC: multiple fixed
MLC segments! patterns that are often used to deliver IMRT.
D. Operational issues
A number of additional operational issues that can com-
plicate the clinical acceptance and use of MC dose calcula-
tions were described.
~1! User confidence: As with any other dose calculation
method, errors in software coding, input data, or other imple-
mentation problems can potentially lead to computational ar-
tifacts in the dose distribution results. It is possible that an
artifact may be large enough to cause clinically important
errors, yet subtle enough to not be detected by experienced
plan evaluators, especially those used to the results from
more simplistic and approximate calculation algorithms. Due
to the expectation that MC will be very accurate, possible
artifacts may be accepted as real because the perception is
that ‘‘Monte Carlo is more accurate.’’
~2! Calculation speed: MC calculation algorithms are still
slower than desirable for routine clinical use, though the situ-
ation is continuing to improve. Workshop attendees stated
that the time necessary for dose calculations should not ex-
ceed 10 min for a typical 4–6 beam plan, as a goal. For
benchmarking or retrospective studies, longer times ~a
couple of hours! are reasonable, though faster is better. It was
the sense of the group that current MC algorithm/hardware
combinations are becoming fast enough to address this con-
cern, but that further work is required to document that the
expected accuracy of the MC calculations is not lost due to
speed-related compromises in the faster algorithms.
~3! Accuracy: MC is expected to be significantly more
accurate than standard methods, and excellent agreement
with measurements has been shown by numerous research-
ers. However, achieving this high level of accuracy has not
been shown to be routinely achievable without significant
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and/or parameters.
~4! Calibration: Ideally ~with a perfect description of the
machine!, it should be possible to calibrate MC output for
each beam quality via a single reference set of conditions
~e.g., dose/unit fluence at reference depth/SSD for one field
size!. However, at present, empirical adjustment is still
needed.
~5! Statistical fluctuations: Handling statistical fluctua-
tions in the dose distribution present considerations that are
not present for current deterministic calculation algorithms.
The size of these effects may be decreased by the proper
application of variance reduction techniques, however, new
techniques to handle these statistical methods may be useful.
~6! Prescription paradigm: It will likely be necessary to
educate clinicians to not prescribe or evaluate biological ef-
fects based on dose at any one specific voxel, since the MC
dose to any voxel is only known with a given statistical
uncertainty. Even if we choose to allow a statistical uncer-
tainty of 1% in the dose calculation results, that does not
mean that we want the entire dose distribution renormalized
by 61%.
~7! Dose to what?: Considerations of dose to water versus
dose to tissue become relevant with MC since the medium of
dose deposition is required for the calculation. One can cer-
tainly report the doses either way, but at the current time,
there is no significant advantage of one over the other. Clini-
cally, the differences may be relatively unimportant except
perhaps at high energies in bone.
~8! Dose resolution: What resolution is appropriate for the
dose distribution, particularly near tissue interfaces, has not
been determined. This issue is quite important because the
voxel sizes used have a significant effect on calculation time
and interface dose accuracy.
~9! Transition zones: Contaminant electrons figure into
the dose in the buildup region, always a problematic region
for dose calculations. Current MC methods have not really
solved this issue,55 probably due to incomplete solution of
the machine head simulation and/or other limitations to the
phase space of the particles incident on the patient. Likewise,
high-Z implanted materials continue to be a calculational
problem, since CT artifacts must be eliminated for any algo-
rithm, including MC, to achieve accurate results. Currently,
manual editing of CT-derived electron densities is the only
method for handling these problems, and this process is
time-consuming and subjective method. Further work is
clearly warranted.
E. Clinical sites for which Monte Carlo may be useful
The clinical treatments that will benefit most from im-
proved dose calculation accuracy are those for which the
improved accuracy makes possible better informed decisions
about clinical plan optimization. These improved decisions
will include how to deliver more dose to the tumor without
compromising safety and better knowledge of dosimetric
limits for normal tissues. Clinical sites which involve tissue
inhomogeneities or interfaces between regions of differentMedical Physics, Vol. 30, No. 12, December 2003density are likely to benefit, as are sites treated with small
fields, sharply varying intensity distributions, complex sets
of beam modifiers, or other complex treatment techniques
which lead to lateral electron disequilibrium or other effects
which are typically only handled correctly by MC algo-
rithms. Treatments in the head/neck, and thorax ~lung, breast/
chestwall, etc.! are thus obvious candidates due to the sig-
nificant inhomogeneities involved, but other treatment sites
may also be important. Even air filling the rectum can cause
unexpected perturbations to the dose distribution in treatment
of prostate cancer. The shaping of high dose regions around
the clivus in nasopharynx tumors may, in principle, allow
improved coverage of the target; but the advantage to the
patient will be lost if the high-dose region drifts into the
adjacent brain stem because of inadequate accounting for the
effect of surrounding air cavities. Similarly, treatment of
small lung tumors in patients with limited pulmonary reserve
may be greatly advanced by reducing the field margins using
techniques of intensity modulation. Perhaps it will be pos-
sible to reduce the field width by modifying the intensity
profile to compensate for the underdosing at the edges of the
target that would otherwise occur. The required modulation
is difficult to plan correctly with current dose calculation
engines, and implementation would greatly benefit from the
accuracy that MC methods could provide.
Many of these issues become more important for intensity
modulated radiotherapy ~IMRT! treatments, since IMRT
treatments involve complex intensity distributions delivered
by static or dynamic methods which often involve very small
component beams which will be strongly influenced by lat-
eral electron disequilibrium effects. The tightly shaped and
complex dose distributions created by IMRT demand a high
degree of accuracy, and non-MC methods may not be ca-
pable of the desired accuracy. It is anticipated that MC meth-
ods, by correctly taking into account the entire patient and
delivery system, may be able to significantly decrease the
differences between planned and actually delivered doses,
thereby allowing development and delivery of improved
treatment regimens.
Much of our current knowledge of dosimetric limits for
normal tissues is based on simplistic dose calculations. In
order to maintain safety, gain clinical acceptance of the MC
method, and determine the realistic implications of use of
more accurate dose calculations, it will be extremely valu-
able to sponsor studies which recalculate the dose distribu-
tions of retrospective series of patients using MC methods,
and then relate the new and more accurate dose distributions
to clinically observed rates of complications and/or tumor
control. With these kinds of studies, we can make use of
already obtained clinical data to help us understand specifi-
cally where MC dose calculation methods will contribute
most to the improvement of patient outcomes.
V. MONTE CARLO DOSE CALCULATION
VERIFICATION
Before any new technology is implemented for clinical
use, the safety and appropriateness of the technology should
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highly related tasks: validation and verification. Here we will
take validation to be the process by which we confirm that
the MC calculations work as designed ~and that appropriate
databases and cross sections are used!, and verification to be
the checks that the MC calculations give good predictions of
the actual dose distribution that is ~or would be! measured
for each situation. Given the complexity of MC codes, vali-
dation is often assumed by the user based upon the ‘‘pedi-
gree’’ of the code or it is folded into the verification process
which compares the calculated results to those obtained by
direct measurement.
A. Scope
The design of a verification program for MC dose calcu-
lation methods is complicated by the fact that MC methods
are used for two distinct purposes: routine use for clinical
treatment planning, and as a benchmark calculation, often for
situations in which measurements are difficult or impossible
to perform accurately. The scope of verification testing nec-
essary for these two purposes is quite different.
The testing required for clinical use of any dose calcula-
tion algorithm has been described in many publications, in-
cluding the report of AAPM Task Group 53.56 The main
difference for a MC-based algorithm is that, if the algorithm
claims to be more accurate at interfaces between tissues, or
for small fields with lateral electron disequilibrium effects
~for example!, then the commissioning tests should docu-
ment that the claim is appropriate. All clinical commission-
ing is aimed at demonstrating those areas in which the algo-
rithm is accurate, and documenting those situations in which
there is less accuracy than desired ~or claimed!.
The scope of verification testing required for a MC code
to be used for benchmark calculations, or for situations
which are too difficult to measure directly, is much larger.
The MC calculations are in this case expected to give the
correct answer, and the verification testing must convince the
users that the MC calculations are in fact right. To do this,
the MC modeling of the physical processes involved must be
quite complete, and the capability of the algorithm to ‘‘ex-
trapolate’’ past situations in which measurements can be
made must be confirmed by a combination of measurement,
theoretical analysis, and careful algorithmic testing. How to
do this is not straightforward, since our ability to make ac-
curate dosimetric measurements in these complex situations
gets reduced as the situations get more complex—so the in-
terpretation of differences between MC calculations and
measurements gets harder to interpret as situations become
more complex. Further work on more sophisticated measure-
ment techniques or other methods that can help confirm the
accuracy of MC calculation results is needed.
B. Verification experiment design
Many different strategies have been used for designing
verification experiments for dose calculation algorithms. The
kinds of problems for which a MC algorithm is most appli-
cable are quite different than the standard situations ad-Medical Physics, Vol. 30, No. 12, December 2003dressed by model-based algorithms, and the testing require-
ments are thus different. The design of MC verification
experiments should depend on carefully prescribed experi-
mental goals, and should use measurement techniques that
are confirmed to be accurate in the situations involved. Is-
sues to be resolved include the following:
~1! Decision on the scope of the verification that is being
pursued.
~2! What minimum set of measurements is needed to bench-
mark a particular algorithm?
~3! What measurement limitations are deemed acceptable in
order to allow extraction of meaningful benchmark re-
sults?
~4! How does one validate the accuracy of the MC code~s!,
particle transport in the patient, and the derived source
phase space independently?
~5! Can earlier benchmark data be used ~for example, the
benchmark inhomogeneity measurements by Rice57 as
recommended by AAPM TG 5356!, or are those situa-
tions and data too limited to be adequate for the MC
testing?
~6! Should the testing concentrate on situations that stress
the algorithms ~for example, perhaps the accuracy of
transport is best examined at small field sizes, which
have minimal source model requirements, and in hetero-
geneous media, to emphasize the loss of lateral elec-
tronic equilibrium!?
~7! How much effort should be expended to study the influ-
ence of physics transport parameters ~such as the low
energy electron cutoff! on the final dose calculation in
heterogeneous media?
Given that MC dose calculations are far more sophisti-
cated than other calculation algorithms, the level of testing
needs to be more complete. A general consensus among
workshop attendees supported the organization of a working
group to investigate MC algorithm testing, and particularly
the development of one or more benchmark data sets that
could be used to qualify various MC approaches or algo-
rithms. Since different MC approaches use different approxi-
mations or limitations, benchmark verification data sets
should include tests and input from different investigators
with different strategies. Also, agreement on how to measure
the data is essential, and the consensus of a working group
involved in the measurements will be crucial to the data
set~s! being considered as a true benchmark result.
C. Verification results for MC algorithms
A number of presentations on the current state of MC
algorithm verification results were presented. Particularly
within the last two or three years, there have been a number
of publications comparing MC calculations and measured
data for a number of MC codes.13,17–19,39,40,51,58–68 However,
it was clear from the workshop presentations, as well as the
literature, that full sets of verification experiments have not
been completed for any of these codes, and that much work
remains to be done in this area. Decisions about issues to be
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be performed would be an excellent task for a working group
aimed at establishing the basic verification requirements for
MC algorithms and their clinical use.
D. How important are machine-specific variations?
For most calculation algorithms, parameters of the calcu-
lation model are set by the local physicists to ‘‘fit’’ the cal-
culation results to the measured data for each beam of each
accelerator. Whether this mode of operation was appropriate
for MC algorithms led to much discussion:
~1! A number of beam parameters for each accelerator are
‘‘tweaked’’ during installation: does this mean similar
MC parameters should also be ‘‘tweaked’’ locally?
~2! How might these algorithm parameter adjustments affect
the accurate modeling of the beam using MC?
~3! Should adjustments be used to compensate for manufac-
turing variations, such as slight misalignment of the flat-
tening filter?
~4! Is it inappropriate to alter actual physical parameters,
such as the assumed shape or position of the flattening
filter, in order to reach agreement between measured data
and calculations?
~5! Should individual clinics modify MC parameters to force
agreement between MC calculations and measurements
in areas where measurements have significant error bars?
~6! Are the MC calculation predictions more accurate than
the measurement system in some centers, or in particular
dosimetric regions ~e.g., the build-up region!?
~7! How can accelerator manufacturers be convinced to dis-
tribute accurate detailed geometrical and materials infor-
mation on their equipment, so that each individual clinic
is not forced to model each accelerator system indepen-
dently?
~8! Can a quick and easy-to-use MC modeling tool be de-
veloped to help users with the difficult machine model-
ing task?
~9! Should manufacturers provide a standardized set of out-
put data, including phase-space files, that could be used
for quality control of individual modeling attempts?
~10! How much of the accuracy of the MC calculations is
dependent on the specifics of the individual machine,
machine modeling, and local beam measurements?
E. Clinical verification by user
Most calculation algorithms used in clinical treatment
planning are commissioned by the local user, to make sure
that the calculations agree adequately with the locally mea-
sured data, and to document disagreements or limitations of
the algorithm. In the case of MC calculations, it is difficult to
determine how much of this clinical verification testing
should be performed locally. All of the above-discussed is-
sues ~in Sec. V D! also apply here to clinical verification
checks. As concluded above, more experience, sensitivity
analysis, and independent verification checking is necessary
before there is enough experience to determine a recommen-Medical Physics, Vol. 30, No. 12, December 2003dation about how much local verification checking should
occur. This would be a good topic of investigation for a MC
working group.
F. Clinical trials groups and MC
Radiation treatment planning and dose delivery with the
advanced technologies such as 3DCRT and IMRT is not as
straightforward as with conventional radiotherapy tech-
niques. More precise definition of tumor and normal tissue is
necessary as is the need to evaluate all aspects of the treat-
ment plan in three dimensions instead of the more familiar
two dimensions. Multi-institutional clinical trials utilizing
these advanced technologies require a rigorous QA
program.69,70
It is possible that use of MC algorithms may become
practical for credentialing and QA review over the next 3 to
5 years for: ~1! 3D CRT with x rays, ~2! serial tomotherapy
IMRT with binary MLC, ~3! cone-beam IMRT with full-field
MLCs, and ~4! stereotactic radiotherapy using fields colli-
mated by cones and microMLC. MC could be used to vali-
date dose distributions generated by specific vendor planning
and dose delivery systems, including IMRT systems. There is
also potential to use MC codes for recalculation of dose dis-
tributions stored in the Image-guided Therapy Center’s ~ITC!
database, e.g., the RTOG 93-11 lung data which involves
significant tissue heterogeneity. However, before MC simu-
lation is practical for use in clinical trials QA, a great deal of
research and development remains; particularly with regard
to careful and detailed verification testing of the MC codes to
be used.
VI. SUMMARY OF RECOMMENDATIONS
Recommendation 1: Clinical verification of MC algo-
rithms. Many of the issues believed to be the highest priority
for additional investigations and research could be very ef-
fectively handled by a collaborative working group which
includes experts in treatment planning and dose calculation
algorithms, MC algorithms, and measurements. The group
should be charged to evaluate Monte Carlo algorithm issues,
and to determine the best way to overcome the limitations
that have been discussed in this report. Specific goals of this
group should include the following:
~1! Development of standardized Monte Carlo calculation
algorithm benchmark data sets, and an algorithm verifi-
cation procedure based on use of the benchmark data.
~2! Algorithm comparisons using benchmark test cases ~ex-
perimental measurements in homogeneous and heteroge-
neous phantoms!, in order to determine which ap-
proaches and approximations are best in terms of clinical
implementation issues. Specific approaches to validation
issues, variance reduction, de-noising, electron transport
models, and other issues should be studied, compared,
and evaluated.
~3! Development of a process that would promote distribu-
tion of accurate MC machine modeling data from manu-
facturers.
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els or simulations of accelerator head geometry.
~5! Development of methods for clinical evaluation and use
of dose distributions with variable statistical uncertainty.
~6! Study of the sensitivity of the Monte Carlo dose calcu-
lations to uncertainties in machine design, machine tun-
ing, and changes known to occur in accelerator compo-
nents over time.
Recommendation 2: Study of the potential clinical impact
of MC. Once the improved accuracy of MC algorithms is
documented, it is crucial to determine how physicians should
learn how to use this more accurate information. Retrospec-
tive dose assessments of already existing clinical complica-
tions and local control data, using doses predicted with im-
proved accuracy MC algorithms, may give an early
indication of the clinical benefit of MC calculations, and may
also help physicians determine how to use the new MC
doses. Data from retrospective analyses should eventually
show us how to make use of this information in a prospective
way. This could also effectively be performed using a col-
laborative working group
Recommendation 3: Further MC research areas. A num-
ber of further developments of the Monte Carlo algorithms
should be investigated:
~1! Methods to help to simultaneously confirm accelerator
head modeling, the phase space of particles exiting the
machine, and transport through the patient.
~2! Further study, extension, and verification of the machine
model, including phase-space and source modeling
methods to all relevant situations for radiotherapy dose
calculations.
~3! Additional study of variance reduction techniques, im-
proved computational techniques including parallel pro-
cessing, improved software techniques, and de-noising
are all warranted. What is the sensitivity of the results
for each of these techniques, and what compromises do
they introduce?
~4! Improved electron transport, particularly attempting to
speed the implementation of these calculations.
~5! MC algorithm sensitivity analysis to determine how sen-
sitive dose results are to various data and features of the
MC method. How accurately does each parameter need
to be determined, and which kinds of uncertainty can
lead to significant potential errors in the predicted dose
distributions?
~6! Improved implementation of IMRT delivery techniques
into the MC algorithms, plus verification that the calcu-
lational results accurately predict the actual dose distri-
butions.
~7! Integration of MC calculation algorithms into the inverse
planning/optimization process for IMRT in a time-
effective way.
Recommendation 4: Continuing education. Education of
physicists and physicians on the methods and clinical impli-
cations of Monte Carlo algorithms and their implementationMedical Physics, Vol. 30, No. 12, December 2003is crucial. This should include symposia and training as well
as guidance materials from the vendors and societies. With-
out these efforts, there is the risk of accepting the potential
superior accuracy of MC as fact; while, in reality, it may be
worse than existing computations in clinics which do not
properly implement and understand the method.
Recommendation 5: Brachytherapy, internal sources, in-
travascular brachytherapy. The discussion of the uses of
brachytherapy, internal sources, and intravascular brachy-
therapy related dose calculations using Monte Carlo was be-
yond the scope of the present workshop. It was recom-
mended by the current workshop that additional workshops
should be directed toward such uses, in order to review the
field and determine which issues would benefit from further
attention by the National Cancer Institute.
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